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New therapeutic strategies are needed to treat infections caused
by drug-resistant bacteria, which constitute a major growing
threat to human health. Here, we use a high-throughput technol-
ogy to identify combinatorial genetic perturbations that can
enhance the killing of drug-resistant bacteria with antibiotic
treatment. This strategy, Combinatorial Genetics En Masse (Com-
biGEM), enables the rapid generation of high-order barcoded
combinations of genetic elements for high-throughput multi-
plexed characterization based on next-generation sequencing.
We created ∼34,000 pairwise combinations of Escherichia coli tran-
scription factor (TF) overexpression constructs. Using Illumina
sequencing, we identified diverse perturbations in antibiotic-
resistance phenotypes against carbapenem-resistant Enterobac-
teriaceae. Specifically, we found multiple TF combinations that
potentiated antibiotic killing by up to 106-fold and delivered these
combinations via phagemids to increase the killing of highly drug-
resistant E. coli harboring New Delhi metallo-beta-lactamase-1.
Moreover, we constructed libraries of three-wise combinations
of transcription factors with >4 million unique members and dem-
onstrated that these could be tracked via next-generation se-
quencing. We envision that CombiGEM could be extended to
other model organisms, disease models, and phenotypes, where
it could accelerate massively parallel combinatorial genetics stud-
ies for a broad range of biomedical and biotechnology applica-
tions, including the treatment of antibiotic-resistant infections.
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Antibiotic resistance dramatically reduces the effectiveness ofexisting treatment options for clinical bacterial infections.
Antibiotic-resistant organisms can result in recalcitrant infec-
tions that are challenging to treat with existing antibiotics,
leading to >20,000 deaths a year (1). Concurrently, the anti-
bacterial discovery pipeline has shrunk dramatically, and ongoing
clinical trials for antibacterials often feature derivatives of
compounds for which resistance mechanisms already exist (2).
Recent attention has centered on drug-resistant Gram-negative
bacteria such as carbapenem-resistant Enterobactericeae (CRE)
(3, 4). These strains can use degradative enzymes, such as New
Delhi metallo-beta-lactamase-1 (NDM-1), which can hydrolyze
beta-lactam antibiotics (5). New treatment regimens and adju-
vants to combat antibiotic resistance are urgently needed (6, 7).
Previously, we showed that overexpressing single genes from
constructs that are delivered into bacteria via engineered bac-
teriophages could potentiate the lethality of antibiotics in wild-
type and quinolone-resistant Escherichia coli carrying a chromo-
somal gyrAmutation (8). Expression of one of these genes, lexA3,
suppressed the SOS network that is normally activated in re-
sponse to antibiotic treatment (9–12). In addition, we demon-
strated that overexpression of the double gene combination
csrA + ompF had enhanced antibiotic-potentiating efficacy com-
pared with its individual gene constituents (8). However, this
study identified the single genes and the gene pair via a laborious
one-by-one testing protocol using a candidate gene approach
informed by previous studies (9–14). Based on this strategy, it
would take on the order of n2 steps [abbreviated O(n2), using
order notation from computer science] to construct all pairwise
combinations of n genes and another O(n2) experiments to test
their efficacy. The brute-force nature of this approach restricts
the scale and combinatorial complexity that can be tested when
trying to identify pathways that can modulate antibiotic-resistance
phenotypes.
To overcome these limitations, we developed a high-throughput
platform for the identification of genetic combinations that
potentiate antibiotic activity against clinically relevant drug-
resistance determinants. Here, we describe a technology, termed
Combinatorial Genetics En Masse (CombiGEM), that enables
the rapid generation of high-order barcoded combinations of
genetic elements for high-throughput multiplexed charac-
terization based on next-generation sequencing. We applied
CombiGEM to identify genetic combinations that enhance the
effectiveness of antibiotics against CRE. CombiGEM uses an
iterative cloning strategy beginning with a library of barcoded
DNA elements (Fig. 1A). Restriction digests of pooled vector
and insert libraries, followed by a one-pot ligation reaction,
create a library of genetic combinations with the barcodes in
close proximity to one another. As a result, the identities of each
of the genetic components in a particular construct can be de-
termined by reading the contiguous DNA barcode sequences
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with high-throughput sequencing. From the newly produced
combinatorial library, higher-order combinations can be gener-
ated in fixed amounts of time by using the same procedure,
rather than in exponentially increasing amounts of time.
Therefore, combinatorial libraries can be constructed in a pooled
format without needing to barcode each combination within an
individual reaction. A similar DNA assembly method was de-
scribed for optimizing translational rates in metabolic pathways,
in which hits were individually sequenced to identify the hit
components (15). In contrast, we use high-throughput sequenc-
ing to census the distribution of library members within pooled
populations in a highly multiplexed manner. By comparing
these distributions, we identify changes in the population under
different experimental conditions to link combinatorial geno-
types to specific phenotypes. We anticipate that CombiGEM will
be a broadly useful tool for identifying genetic combinations
conferring a desired phenotype and for altering the gene ex-
pression profile of a cell.
Results
Combinatorial Library Generation and Functional Validation. In this
study, 173 E. coli transcription factors (TFs) and 18 fluorescent
proteins were placed under the control of the anhydrotetracy-
cline (aTc)-inducible PLtetO promoter (SI Appendix, Fig. S1, and
Dataset 1). The TFs chosen represent nearly all E. coli TFs
identified in RegulonDB (16). These expression constructs were
uniquely barcoded and combined through CombiGEM to yield
35,343 possible pairwise combinations (189 ORFs × 187 ORFs,
because some ORFs were rejected due to undesirable cleavage
by restriction enzymes). This pairwise library was introduced into
an E. coli MG1655 strain by electroporation and sequenced on
the Illumina HiSeq platform, which resulted in the recovery of
34,554 combinations—or 98% of all possible combinations—
distributed across the population (Fig. 1B). To ensure that
inserts remained intact, we isolated and sequenced 50 library
members and confirmed that all 50 retained both genetic ex-
pression constructs, including the genes, promoters, and ribosome-
binding sequences.
To assess expression levels from our combinatorial genetic
constructs, including the influence of gene order on expression
levels, we measured fluorescence from all four pairwise combi-
nations of GFP and mCherry as well as single GFP and mCherry
constructs (SI Appendix, Fig. S2). We observed comparable
fluorescence levels for both fluorescent proteins with the GFP–
mCherry and mCherry–GFP constructs and approximately dou-
ble fluorescence signal levels for GFP–GFP and mCherry–
mCherry compared with the single gene constructs (SI Appendix,
Fig. S3A). We also verified the ability of CombiGEM to scale
beyond pairwise libraries through cloning of barcoded GFP and
mCherry inserts to reach three-wise and four-wise combinatorial
constructs (SI Appendix, Figs. S3 B–D and S4). Flow-cytometry
analysis of higher-order combinations showed stepwise increases
in fluorescence with each additional fluorescent gene and com-
parable fluorescence levels regardless of gene order when the
number of fluorescence genes was held constant (SI Appendix,
Fig. S3D).
CombiGEM Library Screening for Genetic Combinations That
Modulate Antibiotic Killing. We applied CombiGEM to discover
TF combinations in our library that could modulate antibiotic
activity against drug-resistant NDM-1 E. coli. We first de-
termined the minimal inhibitory concentrations (MICs) for
a range of antibiotics against an E. coli NDM-1 strain and found
that this MIC profile resembled those of published NDM-1
clinical isolates (SI Appendix, Table S1). This NDM-1 strain was
resistant to ceftriaxone, a third-generation cephalosporin with
broad-spectrum activity that is used clinically to treat pneumo-
nia, bacterial meningitis, and gonorrhea (17, 18). We then in-
troduced the barcoded pairwise TF library into the E. coli NDM-1
strain by electroporation. We primarily sought to identify TF
combinations that could enhance the activity of existing anti-
biotics to which E. coli NDM-1 was resistant. We subjected
pooled NDM-1 strains containing the barcoded pairwise TF
combinatorial libraries to a two-by-two matrix of conditions that
included media with or without aTc induction and media with or
without ceftriaxone treatment (Fig. 1C). We harvested bacterial
cultures under each condition at early and late logarithmic-
growth stages to observe shifting distributions in the barcoded
populations over time. These samples were multiplexed for high-
throughput sequencing on the Illumina HiSeq platform (19).
Fig. 1. Overview, validation, and application of the CombiGEM technology
to identify genetic combinations that combat antibiotic resistance. (A)
Outline of the CombiGEM assembly strategy. Transcription factor (TF) ex-
pression constructs are barcoded (BC), and four restriction sites (1A, 1B, 2A,
2B) are positioned as shown. The pairs 1A/1B and 2A/2B consist of unique
restriction sites that generate compatible overhangs within the pair but are
incompatible with the other pair. The barcoded vectors are pooled and
digested with enzymes 1B + 2A. Inserts are generated from vectors by PCR
and digested with 1A + 2B. A one-pot ligation reaction produces a pairwise
combinatorial library, which can be further digested and ligated with the
same insert pool to produce higher-order combinations. In this work, barc-
odes are separated by 6 base pairs. (B) Distribution of high-throughput se-
quencing reads among combinations in the pairwise library. A total of
1.9 million reads were distributed among 34,554 combinations, recovering
98% of the possible 35,343 pairwise combinations. (C) Experimental outline.
E. coli NDM-1 cells containing a CombiGEM library were diluted into cultures
with and without anhydrotetracycline (aTc) and grown to middle loga-
rithmic phase. Each culture was then further diluted into cultures with and
without antibiotic (Abx), and with and without aTc. DNA from each condi-
tion was harvested at early and late logarithmic-growth stages and pro-
cessed for high-throughput sequencing (HT-seq) with Illumina HiSeq.
Comparisons of abundances of barcoded gene combinations among differ-
ent conditions revealed genotypes that conferred desired phenotypes. (D)
Heatmap of S scores for specific hits across experiments. Combinations
marked as potentiating combinations represent genetic combinations that
drop out upon addition of both ceftriaxone and aTc. Neutral combinations
showed neutral S scores in the presence of both ceftriaxone and aTc. Cef-
triaxone was applied in two different concentrations: 64 μg/mL (low) and
256 μg/mL (high). Gene pairs correspond to numbers 1, qseB + bolA; 2, lrp +
xylR; 3, eCFP + norR; and 4, pdhR + yohL.
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To determine the influence of each combination on NDM-1
viability, we computed statistical S scores to compare each
combination’s abundance in a particular experimental condition
against its abundance in other experiments (SI Appendix).
Combinations that were underrepresented in the presence of
aTc + ceftriaxone, compared with the other experimental con-
ditions, suggested that expression of those gene combinations
conferred potentiation of ceftriaxone. For validation, we ran-
domly selected potentiating hits from the 200 top-scoring com-
binations, as well as controls with neutral S scores (Table 1).
Hierarchical clustering on the combinations and their scores in
each experiment showed clustering by phenotype class (Fig. 1D).
To gauge the influence of gene order in our expression construct,
we also performed hierarchical clustering on these combinations
and their reciprocal configurations. The combinations of the
same phenotype clustered together regardless of gene order in
the constructs (SI Appendix, Fig. S5).
Validation of Hits via Time-Kill Curves. To validate the activity of
these combinations, we cloned each gene pair and tested their
activity individually in time-kill assays against NDM-1 E. coli
(Fig. 2). Each strain was grown to early logarithmic phase and
treated with and without ceftriaxone and with and without aTc.
Aliquots were serially diluted and plated to measure viable cell
densities over 10 h after initiation of treatment. Combinations
identified as leading to potentiation of killing showed significant
amplification of killing by up to 3–5 orders of magnitude in the
presence of aTc + ceftriaxone compared with ceftriaxone alone
or aTc alone (Fig. 2A). The potentiating combinations also
showed significantly greater killing compared with control com-
binations that were randomly selected for relatively neutral S
scores, as well as the NDM-1 E. coli strain with no genetic
combinations (Fig. 2B and SI Appendix, Fig. S6). In addition, the
gene combinations exhibited significantly higher potentiation of
antibiotic activity as pairwise combinations compared with in-
dividual genes, potentially indicating unexpected synergy (Fig.
2C). The potentiating combinations conferred a transient le-
thality, and the cultures did regrow over time. This regrowth was
seen in all antibiotic-treated samples and could be due to anti-
biotic degradation, resistant subpopulations, or other mecha-
nisms that are yet to be determined.
To further study whether CombiGEM could identify genetic
combinations across a range of antibiotics, we exposed the
pairwise combinatorial library to the beta-lactam imipenem, the
combination beta-lactam and -lactamase inhibitor piperacillin-
tazobactam, and the aminoglycoside antibiotic gentamicin.
Along with ceftriaxone, each antibiotic is used widely in clinical
scenarios and is highly resisted by the NDM-1 strain (20–22). We
performed hierarchical clustering of the top hits across all con-
ditions based on S scores. Hits for the beta-lactam antibiotics in
the presence of aTc clustered together—likely due to their
similar mechanisms of action—and separately from gentamicin,
likely due to their distinct mechanisms of action (SI Appendix,
Fig. S7).
Table 1. S and log-ratio scores for the genetic combinations
studied
Genetic combinations S score Log-ratio score
Potentiating genes (Fig. 2A)
qseB + bolA −1.938 −2.127
lrp + xylR −1.873 0.774
Control genes (Fig. 2B)
eCFP + norR −0.164 −1.120
pdhR + yohL 0.607 1.170
Lethal genes (Fig. 3A)
torR + metR −0.523 −4.336
allR + metJ −1.053 −4.188
nhaR + melR −0.130 −4.103
malI + yfeT −0.543 −3.726
Control genes (Fig. 3B)
rstA + oxyR 0.756 −0.409
cadC + allR −0.145 −1.209
S scores shown are mean S scores for the aTc + ceftriaxone (256μg/mL)
condition taken in early and late logarithmic phases. See SI Appendix for
more details.
Fig. 2. Antibiotic time-kill curves for NDM-1 E. coli with genetic combina-
tions identified through CombiGEM. (A) Interacting gene pairs. Potentiating
combinations identified through S-score analysis, qseB + bolA and lrp + xylR,
exhibited enhancement of ceftriaxone activity upon induction with aTc, with
up to 3–5 orders of magnitude greater killing compared with ceftriaxone
alone or aTc alone. (B) Control genetic combinations with neutral S scores
showed only minor potentiation of ceftriaxone. E. coliMG1655 cells with no
genetic combinations (labeled MG1655) were effectively killed by ceftriax-
one down to the limit of detection (100 CFU/mL). NDM-1 E. coli with no
genetic combinations (labeled NDM-1) exhibited significantly less killing by
ceftriaxone compared with E. coli MG1655. (C) Individual constituent genes
of potentiating combinations revealed less effective potentiation of cef-
triaxone than the corresponding combinations. In all experiments in this
figure, ceftriaxone was administered at a concentration of 192 μg/mL and
aTc at 100 ng/mL. Error bars represent SEM (small error bars are obscured by
symbols).
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Identifying Lethal Genetic Combinations Through CombiGEM. We
next questioned whether CombiGEM could identify combina-
tions of genes that were significantly lethal upon overexpression
but that would also enhance bacterial killing by ceftriaxone. We
identified the strongest lethal combinations by calculating the
log-ratio of abundances between conditions with and without
aTc, averaged across treatments with ceftriaxone and no cef-
triaxone (SI Appendix). We selected random combinations from
the top 200 hits with the lowest log ratios (Table 1). We dis-
covered combinations that showed up to 6 orders of magnitude
greater killing of the bacterial population when used in combi-
nation with ceftriaxone compared with ceftriaxone alone (Fig.
3A). Furthermore, in the absence of concomitant antibiotic
treatment, hits identified from the log-ratio method showed
greater lethality upon induction with aTc (Fig. 3A) compared
with hits identified through the S-score method (Fig. 2A).
Because a majority of E. coli ORFs have been reported to
show growth inhibition upon induction (23), we constructed
random combinations containing previously identified toxic
genes to assess whether CombiGEM could identify especially
lethal combinations (23). Combinations identified through the
log-ratio method showed 1–3 orders of magnitude greater killing
at the points of lowest cell density compared with random
combinations of toxic genes, as well as longer sustained killing
over the period of 10 h tested (Fig. 3 A and B). We also assessed
whether the large killing effects of the genetic combinations were
enhanced over that of the two constituent genes individually
(Fig. 3C and SI Appendix, Fig. S8). Although torR and metR were
toxic and increased antibiotic killing when expressed individually,
the combination of the two genes resulted in greater lethal
effects against NDM-1 bacteria (Fig. 3C). CombiGEM can
therefore isolate combinatorial perturbations leading to strong
phenotypes that are not ex ante apparent from the combination’s
individual constituents.
Gene combinations identified through CombiGEM could be
effective adjuvants for antibiotic treatment if delivered, for ex-
ample, by phage. Previous studies have shown reductions in
bacterial resistance (8, 24) and persistence (8) via phage delivery
of gene expression constructs, but they relied on candidate gene
approaches rather than high-throughput experimental screening
as shown here. We packaged combinatorial genetic expression
phagemids (identified in Fig. 3A) into M13 phage particles and
infected an E. coli EMG2 NDM-1 strain (Fig. 4A). After 30 min
of infection, aTc and ceftriaxone were added where appropriate,
and viable cell counts were obtained on the bacterial cultures.
The induction of gene combinations identified above in con-
junction with ceftriaxone led to enhanced bacterial killing of 1–2
orders of magnitude compared with ceftriaxone alone, whereas
a control phage showed no improvement (Fig. 4B). These results
demonstrate that combinatorial genetic targets identified through
this high-throughput approach can increase the killing of drug-
resistant bacteria with antibiotic treatment.
Scalability of CombiGEM Assembly to Higher-Order Libraries. To
validate the scalability of the CombiGEM technology to higher-
order combinations, we constructed three-wise combination li-
braries from the pairwise TF library with one-pot reactions. We
first produced a lower-complexity library combining 189 × 187 × 18
genes. Out of 636,174 possible combinations, we recovered
582,433 unique combinations (92% of all possible combinations)
from ∼30 million Illumina sequencing reads (SI Appendix, Fig.
S9A). We also produced a higher-complexity library combining
189 × 187 × 187 genes. Out of 6,609,141 possible gene combi-
nations, we recovered 4,042,316 combinations (61%) from
∼20 million sequencing reads (SI Appendix, Fig. S9B). Greater
library coverage could likely be achieved by scaling up bacterial
transformations of the libraries and dedicating a greater number
of sequencing reads to each sample.
Discussion
In this study, we applied CombiGEM to identify TF combina-
tions conferring strong phenotypes relevant to combating anti-
biotic resistance, including enhancement of bacterial killing by
beta-lactam antibiotics against antibiotic-resistant E. coli NDM-1
strains. Most of the single genes and their combinations identi-
fied here have not been reported to directly mediate enhanced
killing by antibiotics. For instance, qseB and bolA are implicated
in pathways associated with virulence (25) and stress response
(26), respectively, and show significantly higher potentiation of
antibiotic activity as pairwise combinations compared with the
individual genes. Thus, CombiGEM can reveal unexpected
interactions between pathways yielding strong phenotypes and
empower systems-biology approaches to uncovering network
interactions. Future work should explore potential mechanisms
Fig. 3. Lethal genetic combinations potentiate antibiotic activity against
NDM-1 bacteria. (A) Interacting gene pairs. When used in combination with
ceftriaxone, lethal genetic combinations identified via log-ratio analysis
achieved reductions of viable cell counts of up to 6 orders of magnitude and
suppressed growth for over 10 h in time-kill assays. (B) Control gene pairs.
Random combinations with lethal genes, such as rstA + oxyR and cadC + allR,
showed significantly less potentiation of antibiotic activity of ceftriaxone
and less sustained growth suppression over time compared with lethal
combinations identified through CombiGEM. (C) Individual genes. The single
gene constituents of the torR + metR combination had weaker effects on
bacterial killing compared with the torR + metR combination, when applied
together with ceftriaxone. In all experiments in this figure, ceftriaxone was
administered at 192 μg/mL and aTc at 100 ng/mL. Error bars represent SEM
(small error bars are obscured by symbols).
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of action of these genetic combinations on antibiotic efficacy,
which could be due to reduction of antibiotic hydrolysis, influ-
encing drug uptake or efflux, increasing the effectiveness of re-
sidual antibiotic, or other effects.
Genetic combinations identified through CombiGEM-based
screens could potentially enhance the treatment of bacterial
infections by revealing pathways that modulate antibiotic re-
sistance and by providing targets for drug screening. The TFs
identified in this study may not be optimal targets themselves
for drug screening given the challenges associated with mod-
ulating TFs with small molecules (27). However, analysis of
the downstream targets modulated by TF combinations using
transcriptomic and proteomic approaches could help to identify
candidate genes for further study. For example, the transcriptomic
profiles of cells with specific genetic combinations could be
compared with cells containing the corresponding constituent
components as well as wild-type cells to identify genes that are
uniquely up- or down-regulated. These genes could then be
knocked out, knocked down, or overexpressed individually,
and in combination with each other, to map their effects on
antibiotic activity.
In future work, CombiGEM could also be used to barcode and
screen combinatorial genetic knockdowns based on approaches
such as antisense RNA (28) and CRISPR interference (29, 30).
The potential advantage of screening for combinatorial knock-
downs that enhance antibiotic efficacy is that such candidates
could be more easily adapted into drug screening pipelines for
small-molecule inhibitor screens. These drugs could then be
delivered in combination treatment with antibiotics to improve
antimicrobial activity. However, there are associated challenges
with delivering combinatorial therapies to target sites at the
same time that may need to be overcome (31).
In this work, we primarily studied the effects of beta-lactam
antibiotics, but the study can be extended to a greater variety
of antibiotics. Furthermore, the antibiotics can be dosed over
a range of concentrations, and the samples can be assayed at
multiple time points to provide greater insights into the inter-
actions between genetic combinations and potential time-
dependent and/or concentration-dependent effects. For example,
beta-lactam antibiotics exhibit time-dependent killing, whereas
quinolone antibiotics exhibit concentration-dependent killing
(32). Moreover, the workflow described in this study identifies
combinations generally leading to a drop in representation in the
library population and does not explicitly distinguish between
bacteriostatic vs. bactericidal activity. However, the protocol
could be further adapted to identify combinations with such
distinct behaviors, for example by quantifying barcode fre-
quencies relative to standard combinations that have known
phenotypes.
More generally, multifactorial genetics are integral to many
complex biological phenomena. Discovery of the underlying
combinatorial effectors has been limited by current methods but
can be enabled by CombiGEM. Differentiation (33, 34) and
reprogramming (35) protocols, such as those for inducing plu-
ripotent stem cells (36), require specific combinations of factors
that are typically discovered through nonmultiplexed and labor-
intensive processes. Similarly, combinatorial drug therapy can
achieve greater efficacy than individual drugs in disease man-
agement (37), but validating large numbers of drug-target com-
binations is difficult. Finally, methods such as genome-wide
association studies have discovered numerous loci putatively
involved in complex diseases, such as heart disease (38) and di-
abetes (39), but aggregated individual loci usually account for
only a minor fraction of the disease heritability (40). Epistatic
interactions between genes have been suggested to account for
part of this “missing heritability,” (41, 42) but experimentally
validating large numbers of such interactions is difficult. In
particular, current methods for screening combinatorial genetic
perturbations are limited in throughput and complexity. Single-
gene overexpression and knockout libraries (23, 43) can be
screened for cellular phenotypes but lack combinatorial com-
plexity. Methods such as synthetic genetic arrays (44, 45) or
double plasmid transformations enable pairwise gene combina-
tion studies but require time-intensive screening of individual
clones. Pooled PCR stitching methods, such as Stitch-Seq (46),
permit higher-throughput screening of pairwise genetic pertur-
bations for interactome mapping. However, these methods
are challenging to scale to three-wise and even higher-order
genetic combinations.
In contrast to existing techniques, next-generation sequencing
applied to the scalable CombiGEM assembly strategy enables
multiplexed tracking of pooled combinatorial populations. By
using this strategy, the one-time construction of the initial library
containing n members proceeds in linear [or O(n)] time, scaling
the library an order higher (e.g., from a pairwise n × n library to
a three-wise n × n × n library, and so forth) proceeds in constant
[or O(1)] time, and characterization of any of the combinatorial
libraries proceeds in O(1) time. The CombiGEM strategy is
flexible and can be used to build high-order combinations of
other DNA elements, including gene-expression and knockdown
(47, 48) constructs, synthetic circuit components, and genomic
sequences, all of which are readily available in libraries. We have
focused on antibiotic-resistant bacteria in this study, but this
approach can also be generalized to study combinatorial ge-
netics in other model organisms, including other bacterial
pathogens, simple eukaryotes such as yeast, and human cells.
For example, combinatorial genetic studies in Staphylococcus
aureus and Pseudomonas aeruginosa could be performed by
constructing libraries in E. coli on shuttle vectors, adapting
expression constructs with validated promoters and ribosome-
binding sequences from the target species, and performing
bacterial transformation of these libraries into S. aureus and
P. aeruginosa for testing. Factors to consider when extending
CombiGEM to other organisms include the availability of trac-
table genetic tools, the efficiency of DNA delivery, the scale of
cell culturing, and thus the possible library complexity that can
be screened.
In future work, CombiGEM could also be extended to gen-
erate complex interactome datasets (49), screen for combinato-
rial regulators of desired phenotypes such as differentiation (36),
identify potentiators of anticancer drugs (50), enhance pathway
Fig. 4. Phagemid-based delivery of genetic combinations enhance killing of
NDM-1 E. coli with ceftriaxone. (A) NDM-1 E. coli were infected with M13
phagemids containing combination constructs and treated with antibiotic
and aTc where appropriate, which is indicated as time t = 0 on the following
graphs. (B) Phagemids containing torR + metR and nhaR + melR, when
coadministered with ceftriaxone and induced with aTc, achieved amplified
killing of NDM-1 E. coli bacteria. (C) In contrast to the results in B, phagemid-
based delivery of a control genetic combination did not result in enhanced
killing of NDM-1 E. coli. In all experiments in this figure, ceftriaxone was
administered at 192 μg/mL and aTc at 100 ng/mL. Error bars represent SEM
(small error bars are obscured by symbols).
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engineering (15), and characterize synthetic circuits at greater
scales (51–55). The CombiGEM assembly strategy can be
adapted to isothermal Gibson assembly (56) or recombinases
(57) in situations where the library is incompatible with re-
striction sites. In summary, by leveraging one-pot combinatorial
DNA assembly with highly multiplexed DNA sequencing of
combinatorial barcodes, CombiGEM collapses high-dimensional
combinatorial genetic studies into straightforward procedures. We
envision that high-throughput strategies for probing multifactorial
phenotypes and emergent network properties will contribute
to our understanding of complex biological systems and their
applications.
Methods
Gene expression constructs were created through isothermal Gibson as-
sembly. Further experimental methods are available in SI Appendix. Details
of data analysis are also found in SI Appendix.
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